Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02425956 · ClinicalTrials.gov registry record · NA
Non-invasive Quantification of Liver Iron With MRI
A NA study, sponsored by GE Healthcare.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
NCT02425956: Completed NA study, sponsored by GE Healthcare.
NCT02425956 is a NA study that has completed, run by GE Healthcare. The registered enrollment target is 21 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02425956, a NA study, has completed, sponsored by GE Healthcare.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is being conducted to build a library of prospectively collected clinical data from subjects with iron overload examined with commercially available MRI devices. This data library is intended for use in future engineering development and other research activities, including future regulatory submissions.
Primary Outcome
The primary outcome measure is collection of evaluable (based on physician determination) MR DICOM datasets including valid 1.5 and 3.0T image data, P-file, R2\* maps, and raw data for each enrolled subject. The datasets were gathered via three independent MR scans conducted within a three hour time block, with up to ten minutes break in between.
Interventions
- DEVICE GE Optima/Discovery® MRI data of the liver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-06-30 |
| Phase | NA |
What the finished NCT02425956 record still lists
NCT02425956 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which GE Optima/Discovery® MRI data of the liver is the first listed.
NCT02425956 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02425956 about?
NCT02425956 is a clinical study titled "Non-invasive Quantification of Liver Iron With MRI". This study is being conducted to build a library of prospectively collected clinical data from subjects with iron overload examined with commercially available MRI devices. This data library is intended for use in future engineering development and other research activities, including future regulat...
What is the current status of trial NCT02425956?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2015-04. Estimated completion is 2016-06-30.
What interventions are being tested in trial NCT02425956?
The interventions under investigation include: GE Optima/Discovery® MRI data of the liver (DEVICE).
Who is sponsoring clinical trial NCT02425956?
This trial is sponsored by GE Healthcare, which has 99 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02425956's enrollment target sits among peer trials
21 1762nd of 2000 higher than 233 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia